Johnson & Johnson (JNJ) Monday reported positive data from Phase 3 QUASAR long-term extension study of TREMFYA in adults with moderately-to-severely active ulcerative colitis (UC).
Results from the study showed that patients treated with TREMFYA sustained clinical and endoscopic efficacy at Week 92. More than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92. Additionally, safety data were consistent with the safety profile of TREMFYA in inflammatory bowel disease (IBD) with no new safety concerns identified.
In September last year, TREMFYA was approved by the FDA for the treatment of adult patients with moderately to severely active UC. The drug is also approved in Plaque Psoriasis, Psoriatic Arthritis, and Crohn's Disease.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.